Education
About Us
Working with TipRanks
Follow Us
Tecan Group AG (CH:TECN)
:TECN
TECN Stock Chart & Stats
CHF117.40
CHF1.00(0.54%)
At close: 4:00 PM EST
CHF117.40
CHF1.00(0.54%)
Day’s Range― - ―
52-Week RangeCHF112.90 - CHF181.70
Previous CloseN/A
Volume42.71K
Average Volume (3M)44.12K
Market Cap
CHF1.51B
Enterprise ValueCHF1.56B
Total Cash (Recent Filing)CHF397.00M
Total Debt (Recent Filing)CHF322.04M
Price to Earnings (P/E)28.7
Beta1.13
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.31%
Share Statistics
EPS (TTM)-10.15
Shares Outstanding12,825,883
10 Day Avg. Volume56,389
30 Day Avg. Volume44,118
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)1.80
Price to Sales (P/S)2.77
P/FCF Ratio21.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF165.66Price Target Upside41.11% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)6.25
Revenue Forecast (FY)CHF883.77M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent strong free cash flow provides durable financial flexibility: it funds R&D, service networks, and the CHF 120m buyback without increasing leverage. Over 2-6 months this cash conversion supports reinvestment, steadies dividends/buybacks and buffers cyclical revenue swings.
Strong Equity PositionA robust equity ratio and declining leverage enhance resilience to macro shocks and give management scope for strategic investments or M&A. This durable balance-sheet strength lowers refinancing risk, supports capital spending for automation product lines and preserves optionality through downturns.
Healthy Orderbook & InnovationA book-to-bill >1 plus new products (Veya workstation, Duo Digital Dispenser) point to sustainable demand and expanding addressable market in Life Sciences. Durable product pipeline and improving Life Sciences sales underpin recurring consumable/service revenue and long-term customer stickiness.
Bears Say
Revenue Decline TrendSustained revenue declines reduce operating leverage and can compress margins and ROE over multiple quarters. If top-line weakness persists it limits reinvestment capacity, pressurizes realized margins and may force deeper cost actions that impair long-term growth initiatives.
China Demand WeaknessProlonged weakness in China, a key market for diagnostics and automation, is a structural risk to growth. Delays in tenders and subdued demand can persist for quarters, reducing partner activity, slowing consumable repeat sales and limiting expansion in a market critical to global life-science end demand.
Partnering Business ContractionA material decline in the Partnering segment signals revenue concentration and execution risk from partners and inventory normalization. Structural partner volatility lowers predictability of service and royalty flows, making overall revenue growth and margin recovery more uncertain over the medium term.
Tecan Group AG News
TECN FAQ
What was Tecan Group AG’s price range in the past 12 months?
Tecan Group AG lowest stock price was CHF112.90 and its highest was CHF181.70 in the past 12 months.
What is Tecan Group AG’s market cap?
Tecan Group AG’s market cap is CHF1.51B.
When is Tecan Group AG’s upcoming earnings report date?
Tecan Group AG’s upcoming earnings report date is Aug 19, 2026 which is in 155 days.
How were Tecan Group AG’s earnings last quarter?
Tecan Group AG released its earnings results on Mar 16, 2026. The company reported -CHF10.15 earnings per share for the quarter, missing the consensus estimate of CHF3.39 by -CHF13.54.
Is Tecan Group AG overvalued?
According to Wall Street analysts Tecan Group AG’s price is currently Undervalued.
Does Tecan Group AG pay dividends?
Tecan Group AG pays a Annually dividend of CHF3 which represents an annual dividend yield of 2.31%. See more information on Tecan Group AG dividends here
What is Tecan Group AG’s EPS estimate?
Tecan Group AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tecan Group AG have?
Tecan Group AG has 12,825,883 shares outstanding.
What happened to Tecan Group AG’s price movement after its last earnings report?
Tecan Group AG reported an EPS of -CHF10.15 in its last earnings report, missing expectations of CHF3.39. Following the earnings report the stock price went down -3.374%.
Which hedge fund is a major shareholder of Tecan Group AG?
Currently, no hedge funds are holding shares in CH:TECN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. It also develops and manufactures laboratory instrument manufacturers with essential components comprising precision pumps, valves, robotic arms, and developer software for life science research, diagnostics, and various other industries; Synergence, platform-based automation solution; and Freedom EVO and Fluent instruments. The company operates in Switzerland and Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.
TECN Company Deck
TECN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While Tecan reported strong order entry and growth in the Life Sciences business, challenges in China, a decline in the Partnering Business, and external factors such as tariffs and currency impacts posed significant challenges. The company's strategic initiatives in cost reduction and innovation are positive, but the current market environment remains difficult.View all CH:TECN earnings summariesTECN Stock 12 Month Forecast
Average Price Target
CHF165.66
▲(41.11% Upside)
Technical Analysis
Medacta Group SA
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
SKAN Group AG
―
Medartis Holding AG
―
Options Prices
Currently, No data available
---